Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Anagrelide/phentermine

Takotsubo cardiomyopathy: case report

    • 23 Accesses

    This is a preview of subscription content, log in to check access.

    REFERENCE

    1. 1.

      Dziewierz A, Olszanecka A, Wilinski J, Rakowski T, Kleczynski P, Dubiel JS, Dudek D.Inverted takotsubo cardiomyopathy in a patient with essential thrombocythemia exposed to anagrelide and phentermine. International Journal of Cardiology 160: e31-e32, No. 2, 4 Oct 2012. Available from: URL: http://dx.doi.org/10.1016/j.ijcard.2012.01.045 - Poland

    Download references

    Additional information

    Key words

    Phentermine; Anagrelide; adverse reactions; drug-induced; Takotsubo-cardiomyopathy

    An event is serious (FDA MedWatch definition) when the patient outcome is: death; life-threatening; hospitalisation; disability; congenital anomaly; requires intervention to prevent permanent impairment or damage

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Anagrelide/phentermine. React. Wkly. 1427, 7 (2012). https://doi.org/10.2165/00128415-201214270-00019

    Download citation

    Keywords

    • Creatine Kinase
    • Regional Wall Motion
    • Takotsubo Cardiomyopathy
    • Regional Wall Motion Abnormality
    • Phentermine